FDA Grants Genentech ’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
Genentech ’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Positive Phase III Results of Genentech ’s Investigational Medicine OCREVUS™ (Ocrelizumab) Published in New England Journal of Medicine
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference
Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
Chugai's Bispecific Antibody "Emicizumab" for Hemophilia A Meets Primary Endpoint in Phase lll Study
Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...
Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...